AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor

Nat Med. 1998 Jan;4(1):72-7. doi: 10.1038/nm0198-072.

G A Donzella ¹, D Schols, S W Lin, J A Esté, K A Nagashima, P J Maddon, G P Allaway, T P Sakmar, G Henson, E De Clercq, J P Moore

Affiliations

Affiliation

1 The Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA.

PMID: 9427609 DOI: 10.1038/nm0198-072

Abstract

The bicyclam AMD3100 (formula weight 830) blocks HIV-1 entry and membrane fusion via the CXCR4 co-receptor, but not via CCR5. AMD3100 prevents monoclonal antibody 12G5 from binding to CXCR4, but has no effect on binding of monoclonal antibody 2D7 to CCR5. It also inhibits binding of the CXC-chemokine, SDF-1alpha, to CXCR4 and subsequent signal transduction, but does not itself cause signaling and has no effect on RANTES signaling via CCR5. Thus, AMD3100 prevents CXCR4 functioning as both a HIV-1 co-receptor and a CXC-chemokine receptor. Development of small molecule inhibitors of HIV-1 entry is feasible.

Name
Email *

	Sorry, but the email address you supplied was invalid.